R&D channel feed

Roche's check­point play­er Tecen­triq flops in an­oth­er blad­der can­cer sub­set

6 years ago

Eli Lil­ly’s $1.6B can­cer drug failed to spark even the slight­est pos­i­tive gain for pa­tients in its 1st PhI­II

6 years ago

Pas­cal So­ri­ot and As­traZeneca com­mit to ze­ro-car­bon by 2025, car­bon-neu­tral by 2030. Where's the rest of Phar­ma?

6 years ago

New play­ers are jump­ing in­to the scram­ble to de­vel­op a vac­cine as pan­dem­ic pan­ic spreads fast

6 years ago

Fresh tri­al da­ta for­ti­fy po­si­tion of Roche's oral ther­a­py in spinal mus­cu­lar at­ro­phy bat­tle­ground

6 years ago

Tran­si­tion­al lead­ers take charge as FDA be­gins PhI­II of OND re­or­ga­ni­za­tion

6 years ago

Io­n­is, Akcea boost­ed by a pos­i­tive PhII for their No­var­tis castoff car­dio drug — and they plan to push ahead in­to piv­otals

6 years ago

What do Mass Gen­er­al, the NCI and Mayo Clin­ic have in com­mon? They rou­tine­ly blow off an FDA rule on post­ing tri­al re­sults

6 years ago

GSK’s ‘break­through’ BC­MA can­cer drug gets a pri­or­i­ty re­view — and a big win for the on­col­o­gy R&D team

6 years ago

BeiGene lines up its first shot at crack­ing the megablock­buster PD-1 mar­ket for lung can­cer. But can they over­come un­der­dog sta­tus?

6 years ago

Sci­en­tists find un­ex­pect­ed an­ti-can­cer ac­tiv­i­ty in range of non-on­col­o­gy drugs — study

6 years ago
Discovery

As­traZeneca nabs pri­or­i­ty re­view for Lyn­parza in prostate as PARP in­hibitors ex­pand to more can­cers

6 years ago

Rev­o­lu­tion Med shoots for $100M+ IPO — and di­vulges some se­crets about that Warp Dri­ve buy­out

6 years ago

At #JPM20, two CEOs, two rad­i­cal­ly dif­fer­ent ther­a­pies, and a fight to chase down sick­le cell

6 years ago
Cell/Gene Tx
In Focus

No­vo Nordisk's block­buster Ozem­pic wins FDA la­bel boost with CV in­di­ca­tion

6 years ago

Hung ju­ry vote leaves FDA with a dif­fi­cult de­ci­sion on Durec­t's non-opi­oid painkiller

6 years ago
FDA+

Bio­Marin ex­ecs dis­cuss some eye-pop­ping num­bers for the price of val­rox — but haven't we heard this be­fore?

6 years ago

#JPM20: Five years af­ter first PC­SK9, No­var­tis goes for win as Sanofi moves on, Am­gen sal­vages what's left

6 years ago

The FDA: Faster, but not nec­es­sar­i­ly bet­ter. And that could threat­en the agen­cy's brand

6 years ago
FDA+

#JPM20 ex­clu­sive: Olivi­er Brandi­court fol­lows the Big Phar­ma CEO path to pri­vate eq­ui­ty, join­ing Black­stone ahead of a mam­moth fund de­but

6 years ago
People

Neon Ther­a­peu­tics makes one last re­treat, sell­ing it­self cheap in a bar­gain base­ment M&A deal

6 years ago
Deals

#JPM20: Af­ter a year of NASH col­laps­es, all eyes on two biotechs

6 years ago
In Focus

Nek­tar aban­dons opi­oid drug af­ter a unan­i­mous 27-0 re­buff from FDA ad­comm

6 years ago

Four years af­ter 'moon­shot' launch, Patrick Soon-Sh­iong has a big re­veal: a sin­gle pa­tient

6 years ago
First page Previous page 214215216217218219220 Next page Last page
A service from the Financial Times